Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Apellis Pharmaceuticals (APLS) PT Lowered to $65 at Oppenheimer
September 10, 2021 6:58 AM EDTOppenheimer analyst Justin Kim lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $65.00 (from $80.00) while maintaining an Outperform rating.
The analyst commented, "On 9/9, Apellis reported mixed top-line results from its Phase 3 DERBY and OAKS studies (n=1,258) of pegcetacoplan in geographic... More
Apellis Pharmaceuticals (APLS) PT Lowered to $70 at Needham & Company
September 10, 2021 6:54 AM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $70.00 (from $85.00) while maintaining a Buy rating.
The analyst commented, "APLS announced yesterday results from the Ph3 DERBY and OAKS trials evaluating pegcetacoplan in Geographic Atrophy (GA). The... More
Apellis Pharmaceuticals (APLS) PT Lowered to $69 at BMO Capital, Overall Data 'Should Still be Enough'
September 10, 2021 6:40 AM EDTBMO Capital analyst Matthew Luchini lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $69.00 (from $89.00) while maintaining an Outperform rating, saying the "totality of data plus the unmet need in GA provides reasonable basis for approval and recommend taking advantage of current... More
Apellis Pharmaceuticals (APLS) to Resume Trading at 4:35 p.m.
September 9, 2021 4:14 PM EDTApellis Pharmaceuticals (NASDAQ: APLS) to Resume Trading at 4:35 p.m.
UPDATE: IVERIC bio (ISEE) Gains Following Results From Apellis Pharmaceuticals (APLS)
September 9, 2021 4:14 PM EDT(Updated - September 9, 2021 4:22 PM EDT)
IVERIC bio (NASDAQ: ISEE) Strength Post-Market Said Tied to Results from Apellis Pharmaceuticals (NASDAQ: APLS)
Shares Up 17%Update:
Shares Are Now Up 22%Catalyst Biosciences (NASDAQ: CBIO) Also Gained, up 15%... More